Back to discover
Disease

Vomiting

Late-stage therapeutic developmentEmerging research
MeSHVomiting
2
Publications
24
Clinical trials
2018
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 2 clinical trials expected to report results, the earliest in Q1 2027.
  • 2 industry developments reported.
Upcoming Milestones
Clinical Milestones9View all 9
Results expected 2
Recently completed 5
+1 more in the activity timeline below
Industry & Market2View
Activity timeline11

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Palonosetronapproved

Generic approval — Palonosetron Accord is indicated in adults for: the prevention of acute nausea and vomit… (2016)

Granisetronapproved

Original application approval — Prevention of nausea and vomiting in patients receiving moderately or highly emetogenic c… (2012)

Fosaprepitantapproved

Original application approval — Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer… (2008)

Aprepitantapproved

Original application approval — Emend 40 mg hard capsules is indicated for the prevention of postoperative nausea and vom… (2003)

Clinical trials

18 sponsors · 3 new · 4 completed in the last 12 months (net +3)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies

Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting

Phase 3 · Recruiting · Affiliated Hospital of Qinghai University

Combining Electroacupuncture With Antiemetic Therapy for Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer: A Clinical Study

Phase 3 · Recruiting · Feixue Song

Preoperative Ginger for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Cholecystectomy: A Double-Blind Randomized Controlled Trial

Phase 4 · Recruiting · University Tunis El Manar

An Exploratory Study on the Efficacy and Safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in Preventing Nausea and Vomiting Caused by Highly Emetogenic Multi-Agent Chemotherapy

Phase 4 · Recruiting · Shanghai 6th People's Hospital

Antiemetic Fosaprepitant To Remedy Nausea and Vomiting

Phase 2/3 · Recruiting · Montefiore Medical Center

A Study on Electroacupuncture Combined With Olanzapine-contained Four-drug Antiemetic Therapy for the Prevention of Highly Emetogenic Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer (ECO Study)

Phase 3 · Recruiting · Jiuda Zhao
Recruiting

Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting

Phase 3 · Recruiting · Affiliated Hospital of Qinghai University

Combining Electroacupuncture With Antiemetic Therapy for Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer: A Clinical Study

Phase 3 · Recruiting · Feixue Song

Preoperative Ginger for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Cholecystectomy: A Double-Blind Randomized Controlled Trial

Phase 4 · Recruiting · University Tunis El Manar

An Exploratory Study on the Efficacy and Safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in Preventing Nausea and Vomiting Caused by Highly Emetogenic Multi-Agent Chemotherapy

Phase 4 · Recruiting · Shanghai 6th People's Hospital

Antiemetic Fosaprepitant To Remedy Nausea and Vomiting

Phase 2/3 · Recruiting · Montefiore Medical Center

A Study on Electroacupuncture Combined With Olanzapine-contained Four-drug Antiemetic Therapy for the Prevention of Highly Emetogenic Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer (ECO Study)

Phase 3 · Recruiting · Jiuda Zhao
Recently completed

Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients

Phase 3 · Completed · Centre hospitalier de l'Université de Montréal (CHUM)

Series Study on the Application of G Protein-Biased Receptor Agonist Oliceridine in Gynecological Surgery (2)：Effects of Oliceridine Versus Sufentanil on Postoperative Nausea and Vomiting After Gynecological Laparoscopic Surgery

Phase 4 · Completed · YanYing Xiao

A Comparison Between Palonosetron Versus Granisetron As Postoperative Nausea and Vomiting Prophylaxis In Idiopathic Scoliosis Surgery: A Randomized Control Trial

Phase 4 · Completed · University of Malaya

Comparison of Dexmedetomidine and Dexamethasone for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized Controlled Trial

Phase 3 · Completed · Patel Hospital, Pakistan

A Multicenter, Randomized, Double-blind, Double-dummy, Positive-controlled Phase III Trial, to Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy

Phase 3 · Completed · Qilu Pharmaceutical Co., Ltd.

A Randomized Phase III Study Evaluating the Efficacy and Safety of HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents

Phase 3 · Completed · Fujian Shengdi Pharmaceutical Co., Ltd.

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

Product approvals and authorisations
2016emaGeneric approval — Palonosetron· Palonosetron Accord is indicated in adults for: the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy, the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. Palonosetron Accord is indicated in paediatric patients 1 month of age and older for: The prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. source ↗
2012emaOriginal application approval — Granisetron· Prevention of nausea and vomiting in patients receiving moderately or highly emetogenic chemotherapy, with or without cisplatin, for up to five consecutive days. Sancuso may be used in patients receiving their first chemotherapy regimen or in patients who have previously received chemotherapy. source ↗
2008emaOriginal application approval — Fosaprepitant· Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older. Ivemend 150 mg is given as part of a combination therapy. source ↗
2003emaOriginal application approval — Aprepitant· Emend 40 mg hard capsules is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults. Emend is also available as 80 mg and 125 mg hard capsules for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12 (see separate Summary of Product Characteristics). Emend is also available as 165 mg hard capsules for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy in adults and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults. Emend is also available as powder for oral suspension for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in children, toddlers and infants from the age of 6 months to less than 12 years. Emend 80 mg, 125 mg, 165 mg hard capsules and Emend powder for oral suspension are given as part of combination therapy. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
2014–2018
Major themes1
  • Glucagon-Like Peptide-1 Receptor Agonists1
Leading journals2
  • Blood1
  • Molecular metabolism1
Leading researchers8
  • Alsina-Fernandez J1
  • Benson CT1
  • Bokvist KB1
  • Briere DA1
  • Burke JM1
  • Cabrera O1
  • Chen L1
  • Clementi R1
Affiliations (unnormalised)3
  • Duke University Medical Center1
  • Lilly Corporate Center1
  • Sarah Cannon Research Institute/Tennessee Oncology1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

The forcible expulsion of the contents of the STOMACH through the MOUTH.

Identifiers
MeSHVomiting
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.